Moderna's vaccine demonstrated superior efficacy compared to GSK's flu shot on July 1, 2025.
2 reports, 0 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna's vaccine demonstrated superior efficacy compared to GSK's flu shot on July 1, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Positive test results were reported for Moderna's flu vaccine.Sub-event
- Moderna's vaccine showed superior efficacy to GSK's flu shot.
Keep exploring
The entities involved
-
Moderna
American biotechnology company
- Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- Trump administration pushes vaccine approval while FDA moves forward with Moderna vaccine, with Fauci noting incomplete protection.
- Moderna combined its vaccine with Merck's Keytruda drug.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet